Yong Yang

Dr. Yong Yang

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in Carbohydrate Polymers
Verified
Journal Article
Closed access
LSLinlin Sun
Linlin Sun
YLYuting Liu
Yuting Liu
QSQihui Sun
Qihui Sun
GWGuimei Wang
Guimei Wang
BDBaoxiang Du
Baoxiang Du
RRRong Rong
Rong Rong

23 August 2023 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
BDBaoxiang Du
Baoxiang Du
YFYan Fu
Yan Fu
YHYuxiu Han
Yuxiu Han
QSQihui Sun
Qihui Sun
JXJinke Xu
Jinke Xu
RRRong Rong
Rong Rong
Both lung and gut belong to the common mucosal immune system (CMIS), with huge surface areas exposed to the external environment. They are the main defense organs against the invasion of pathogens and play a key role in innate and adaptive immunity. Recently, more and more evidence showed that stimulation of one organ can affect the other, as exemplified by intestinal complications during respiratory disease and vice versa, which is called lung-gut crosstalk. Intestinal microbiota plays an important role in respiratory and intestinal diseases. It is known that intestinal microbial imbalance is related to inflammatory bowel disease (IBD), this imbalance could impact the integrity of the intestinal epithelial barrier and leads to the persistence of inflammation, however, gut microbial disturbances have also been observed in respiratory diseases such as asthma, allergy, chronic obstructive pulmonary disease (COPD), and respiratory infection. It is not fully clarified how these disorders happened. In this review, we summarized the latest examples and possible mechanisms of lung-gut crosstalk in respiratory disease and IBD and discussed the strategy of shaping intestinal flora to treat respiratory diseases.

21 June 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
LSLinlin Sun
Linlin Sun
PZPan Zhao
Pan Zhao
MCMenghan Chen
Menghan Chen
JLJiayi Leng
Jiayi Leng
YLYixin Luan
Yixin Luan
RRRong Rong
Rong Rong

9 September 2023 in The FASEB Journal
Verified
Journal Article
Open access
JYJiangbo Yan
Jiangbo Yan
GFGangning Feng
Gangning Feng
YYYong Yang
Yong Yang
XZXin Zhao
Xin Zhao
Long MaLong Ma
Long Ma
QJQunhua Jin
Qunhua Jin
Synovial inflammation and fibrosis are important pathological changes associated with osteoarthritis (OA). Herein, we investigated if nintedanib, a drug specific for pulmonary fibrosis, plays a positive role in osteoarthritic synovial inflammation and fibrosis. We assessed the effect of nintedanib on osteoarthritic synovial inflammation and fibrosis in a mouse model of OA created by destabilization of the medial meniscus and a macrophage M1 polarization model created by stimulating RAW264.7 cells with lipopolysaccharide. Histological staining showed that daily gavage administration of nintedanib significantly alleviated articular cartilage degeneration, reduced the OARSI score, upregulated matrix metalloproteinase‐13 and downregulated collagen II expression, and significantly reduced the synovial score and synovial fibrosis in a mouse OA model. In addition, immunofluorescence staining showed that nintedanib significantly decreased the number of M1 macrophages in the synovium of a mouse model of OA. In vitro results showed that nintedanib downregulated the phosphorylation levels of ERK, JNK, p38, PI3K, and AKT while inhibiting the expression of macrophage M1 polarization marker proteins (CD86, CD80, and iNOS). In conclusion, this study suggests that nintedanib is a potential candidate for OA treatment. The mechanisms of action of nintedanib include the inhibition of M1 polarization in OA synovial macrophages via the MAPK/PI3K‐AKT pathway, inhibition of synovial inflammation and fibrosis, and reduction of articular cartilage degeneration.

14 October 2016 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
YYYong Yang
Yong Yang
HCHan Cheng
Han Cheng
HYHui Yan
Hui Yan
PWPeng-Zhan Wang
Peng-Zhan Wang
RRRong Rong
Rong Rong
Lijun RongLijun Rong
Lijun Rong

12 October 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LZLiangxin Zhao
Liangxin Zhao
SQShensi Qian
Shensi Qian
XWXu Wang
Xu Wang
TSTiantian Si
Tiantian Si
JXJinke Xu
Jinke Xu
RRRong Rong
Rong Rong